Adrenergic beta-1 receptor (ADRB1)

Molecular Classification

G protein-coupled receptor (GPCR), Receptor, Adrenergic receptor family

Other Names

Beta-1 adrenergic receptor, β1-adrenoceptor, β1AR, ADRB1

Disease Roles

Cardiovascular disease (hypertension, heart failure, arrhythmias, myocardial infarction)Other (role in some tumors and glaucoma; rarely, psychiatric implications with antagonists)

Adrenergic beta-1 receptor Overview

The Adrenergic beta-1 receptor is a transmembrane protein of the large G protein-coupled receptor (GPCR) family, predominantly expressed in cardiac tissue. It mediates the stimulatory actions of endogenous catecholamines (epinephrine and norepinephrine) via coupling to Gs proteins, leading to increased heart rate, contractility, and renin release. Selective antagonists (beta-1 blockers) are widely used in medicine to treat hypertension, heart failure, angina, myocardial infarction, and arrhythmias by dampening sympathetic output to the heart. Selectivity for the beta-1 subtype helps minimize adverse effects in airway and metabolic regulation. This target’s role in cardiovascular homeostasis and disease makes it a critical focus for both pharmacology research and clinical therapy.

Mechanism of Action

Agonists: Bind and activate ADRB1, increasing heart rate and contractility. Antagonists (beta blockers): Bind and inhibit ADRB1, reducing heart rate, contractility, blood pressure, and oxygen demand.

Biological Functions

Signal transduction

Regulation of heart rate and cardiac contractility

Stimulation of renin release (in kidneys)

Regulation of lipolysis (fat metabolism)

Disease Associations

Cardiovascular disease (hypertension, heart failure, arrhythmias, myocardial infarction)

Other (role in some tumors and glaucoma; rarely, psychiatric implications with antagonists)

Safety Considerations

Nonselective beta blocker use in asthmatic patients can cause life-threatening bronchospasm due to cross-reactivity with beta-2 adrenergic receptors
Side effects: bradycardia, hypotension, fatigue, decreased peripheral circulation, acute heart failure exacerbation
Potential for metabolic disturbances and masking signs of hypoglycemia in diabetics

Interacting Drugs

Acebutolol

Atenolol

Betaxolol

Bisoprolol

Esmolol

Metoprolol

Nebivolol

Celiprolol

Carvedilol

Practolol

Dobutamine

Arbutamine

Xamoterol

Epinephrine

Norepinephrine

Etilefrine

Droxidopa

Associated Biomarkers

Biomarker
ADRB1 genetic variants may affect response to beta blockers and heart disease outcomes (clinical relevance evolving; not standard yet)